Search
DEEN
more info

Contact:
Phone:+49 0761 1514 440Fax:+49 0761 1514 460Email:info[at]falkfoundation.org

    Falk Gastro Review Journal

    Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

    Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

    The latest issues

    Edition 4/2024

    read more

    Edition 3/2024

    read more

    Edition 2/2024

    read more

    Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

    All articles

    Esophagus to Small Intestine

    The impact of red blood cell transfusion practices on inpatient mortality in variceal and non-variceal gastrointestinal bleeding patients: A 20-year US nationwide retrospective analysis

    Aliment Pharmacol Ther. 2022;56(1):41-55

    Radadiya D, Devani K, Rockey DC

    Go to article

    Esophagus to Small Intestine

    Timing of endoscopy for acute upper gastrointestinal bleeding: A territory-wide cohort study

    Gut. 2022;71(8):1544–50

    Guo CLT, Wong SH, Lau LHS, Lui RNS, Mak JWY, Tang RSY, Yip TCF, Wu WKK, Wong GLH, Chan FKL, Lau JYW, Sung JJY

    Go to article

    Esophagus to Small Intestine

    Over-the-scope clips versus standard treatment in high-risk patients with acute non-variceal upper gastrointestinal bleeding: A randomized controlled trial (STING-2)

    Gut. 2022;71(7):1251–8

    Meier B, Wannhoff A, Denzer U, Stathopoulos P, Schumacher B, Albers D, Hoffmeister A, Feisthammel J, Walter B, Meining A, Wedi E, Zachäus M, Pickartz T, Küllmer A, Schmidt A, Caca K

    Go to article

    Esophagus to Small Intestine

    The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive esophagitis: A phase 3, randomized, double-blind multicenter study

    Aliment Pharmacol Ther. 2022;55(12):1524–33

    Chen S, Liu D, Chen H, Liao A, Li F, Liu C, Li X, Li S, Zhang Y, Wang Y, Xia M, Guo Q, Miao X, Wen Z, Xu M, Yin H, Chen H, Chen M, Xiao Y

    Go to article

    Esophagus to Small Intestine

    Clinical trial: A controlled trial of baclofen add-on therapy in PPI-refractory gastroesophageal reflux symptoms

    Aliment Pharmacol Ther. 2022;56(2):231–9

    Pauwels A, Raymenants K, Geeraerts A, Boecxstaens V, Masuy I, Broers C, Vanuytsel T, Tack J

    Go to article

    Esophagus to Small Intestine

    Risankizumab as induction therapy for Crohn’s disease: Results from the phase 3 ADVANCE and MOTIVATE induction trials

    Lancet. 2022;399(10340):2015–30

    D’Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Jr., Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M

    Go to article

    Esophagus to Small Intestine

    Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: A multicenter, randomized, double-blind, parallel-group, phase 3b trial

    Lancet. 2022;399(10342):2200–11

    Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV, Jr., Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group

    Go to article

    Esophagus to Small Intestine

    Efficacy and safety of infliximab retreatment in Crohn’s disease: A multicenter, prospective, observational cohort (REGAIN) study from the GETAID

    Am J Gastroenterol. 2022;117(9):1482–90

    Boschetti G, Nachury M, Laharie D, Roblin X, Gilletta C, Aubourg A, Bourreille A, Zallot C, Hebuterne X, Buisson A, Grimaud JC, Bouhnik Y, Allez M, Altwegg R, Viennot S, Vuitton L, Carbonnel F, Paul S, Desseaux K, Lambert J, Peyrin-Biroulet L

    Go to article

    Esophagus to Small Intestine

    Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: Results from the multicenter, randomized, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

    Lancet. 2022;399(10340):2031–46

    Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Jr., Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D‘Haens G

    Go to article